Leber congenital amaurosis: clinical correlations with genotypes, gene therapy trials update, and future directions
- PMID: 20006823
- DOI: 10.1016/j.jaapos.2009.10.004
Leber congenital amaurosis: clinical correlations with genotypes, gene therapy trials update, and future directions
Abstract
Leber congenital amaurosis comprises a group of early onset childhood retinal dystrophies, characterized by vision loss, nystagmus, and severe retinal dysfunction. To date, 15 causative genes have been identified that account for the heterogeneous presentation and clinical course. Knowledge of key aspects of phenotype and clinical course can contribute to the determination of a precise genetic etiology using genetic testing. Gene-based therapies are emerging, and knowledge of a patient's genotype is essential. A review of clinical presentation and disease course, their correlation to specific genotypes, and underlying physiological mechanisms, coupled with the latest results of human gene therapy trials, will assist the clinician in patient diagnosis and counseling.
Similar articles
-
My child has Leber congenital amaurosis: why is he/she not eligible for gene therapy trials?J AAPOS. 2009 Dec;13(6):533-4. doi: 10.1016/j.jaapos.2009.09.006. J AAPOS. 2009. PMID: 19896875 No abstract available.
-
The phenotype of Severe Early Childhood Onset Retinal Dystrophy (SECORD) from mutation of RPE65 and differentiation from Leber congenital amaurosis.Invest Ophthalmol Vis Sci. 2011 Jan 5;52(1):292-302. doi: 10.1167/iovs.10-6106. Invest Ophthalmol Vis Sci. 2011. PMID: 20811047
-
Available Evidence on Leber Congenital Amaurosis and Gene Therapy.Semin Ophthalmol. 2017;32(1):14-21. doi: 10.1080/08820538.2016.1228383. Epub 2016 Sep 29. Semin Ophthalmol. 2017. PMID: 27686653 Review.
-
Seeing is believing: gene therapy shows promise for ocular disorders.JAMA. 2010 Oct 13;304(14):1543-5. doi: 10.1001/jama.2010.1412. JAMA. 2010. PMID: 20940376 No abstract available.
-
Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.Expert Opin Biol Ther. 2011 Mar;11(3):429-39. doi: 10.1517/14712598.2011.557358. Expert Opin Biol Ther. 2011. PMID: 21299439 Review.
Cited by
-
Therapeutic applications of CRISPR/Cas9 gene editing technology for the treatment of ocular diseases.FEBS J. 2023 Nov;290(22):5248-5269. doi: 10.1111/febs.16771. Epub 2023 Mar 27. FEBS J. 2023. PMID: 36877952 Free PMC article. Review.
-
Frameshift Variant in AMPD2 in Cirneco dell'Etna Dogs with Retinopathy and Tremors.Genes (Basel). 2024 Feb 13;15(2):238. doi: 10.3390/genes15020238. Genes (Basel). 2024. PMID: 38397227 Free PMC article.
-
Clinical and genetic characteristics of Leber congenital amaurosis with novel mutations in known genes based on a Chinese eastern coast Han population.Graefes Arch Clin Exp Ophthalmol. 2016 Nov;254(11):2227-2238. doi: 10.1007/s00417-016-3428-5. Epub 2016 Jul 16. Graefes Arch Clin Exp Ophthalmol. 2016. PMID: 27422788
-
Quasidominance in autosomal recessive RDH12-Leber congenital amaurosis.Ophthalmic Genet. 2020 Apr;41(2):198-200. doi: 10.1080/13816810.2020.1737949. Epub 2020 Mar 16. Ophthalmic Genet. 2020. PMID: 32172635 Free PMC article. No abstract available.
-
Has retinal gene therapy come of age? From bench to bedside and back to bench.Hum Mol Genet. 2019 Oct 1;28(R1):R108-R118. doi: 10.1093/hmg/ddz130. Hum Mol Genet. 2019. PMID: 31238338 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases